CIAM
CORT icon

Caitong International Asset Management’s Corcept Therapeutics CORT Stock Holding History

Caitong International Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-362
Closed -$14.6K – 3069
2026
Q1 		$14.6K Sell
362
-251,270
-100% -$9.4M ﹤0.01% 1038
2025
Q4 		$8.76M Buy
+251,632
New +$19.8M 2.15% 9
2025
Q2 		– Sell
-37,588
Closed -$4.29M – 2082
2025
Q1 		$4.29M Buy
+37,588
New +$2.29M 3.19% 4

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caitong International Asset Management's CORT Position: Q2 2026 in Review

Caitong International Asset Management sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 362 shares — an estimated $14.6K sold.

Caitong International Asset Management first reported a position in CORT in Q1 2025 and held it in 3 quarters. The position peaked at $8.76M in Q4 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Caitong International Asset Management reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 362 Corcept Therapeutics shares in Q2 2026, an estimated $14.6K.
  • Caitong International Asset Management first reported a position in Corcept Therapeutics in Q1 2025 and held it in 3 quarters.
  • Caitong International Asset Management's Corcept Therapeutics position peaked at $8.76M in Q4 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.